Equities research analysts predict that Aduro BioTech Inc (NASDAQ:ADRO) will report earnings per share of ($0.30) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Aduro BioTech’s earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.37). Aduro BioTech posted earnings of ($0.32) per share during the same quarter last year, which would indicate a positive year over year growth rate of 6.3%. The business is scheduled to announce its next earnings report on Tuesday, May 1st.
On average, analysts expect that Aduro BioTech will report full-year earnings of ($1.29) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.01). For the next year, analysts forecast that the firm will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.71) to $0.03. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01. The firm had revenue of $3.76 million for the quarter, compared to analyst estimates of $4.32 million. Aduro BioTech had a negative net margin of 532.88% and a negative return on equity of 37.86%.
A number of equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Aduro BioTech from a “buy” rating to a “strong-buy” rating in a report on Thursday. Canaccord Genuity reissued a “buy” rating on shares of Aduro BioTech in a report on Friday, March 2nd. Bank of America dropped their price objective on shares of Aduro BioTech from $9.00 to $8.00 and set an “underperform” rating on the stock in a report on Friday, March 2nd. ValuEngine raised shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Wednesday, March 14th. Finally, HC Wainwright set a $10.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $14.50.
Shares of ADRO traded down $0.40 during trading hours on Wednesday, reaching $8.90. 727,741 shares of the company traded hands, compared to its average volume of 603,146. The firm has a market capitalization of $753.36, a PE ratio of -6.20 and a beta of 2.03. Aduro BioTech has a 12-month low of $5.82 and a 12-month high of $14.05.
In other Aduro BioTech news, insider Elsas Andrea Van sold 6,874 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.48, for a total value of $44,543.52. Following the sale, the insider now directly owns 216,669 shares of the company’s stock, valued at $1,404,015.12. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Stephen T. Isaacs sold 7,949 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $7.95, for a total transaction of $63,194.55. Following the completion of the sale, the insider now directly owns 213,695 shares in the company, valued at $1,698,875.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 106,874 shares of company stock worth $870,931. 6.60% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company boosted its holdings in Aduro BioTech by 12.5% in the second quarter. The Manufacturers Life Insurance Company now owns 33,964 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 3,769 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Aduro BioTech by 5.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 174,478 shares of the biotechnology company’s stock worth $1,859,000 after acquiring an additional 9,140 shares during the period. Alps Advisors Inc. raised its position in shares of Aduro BioTech by 12.5% in the fourth quarter. Alps Advisors Inc. now owns 82,678 shares of the biotechnology company’s stock worth $620,000 after acquiring an additional 9,197 shares during the period. Fox Run Management L.L.C. raised its position in shares of Aduro BioTech by 91.4% in the fourth quarter. Fox Run Management L.L.C. now owns 22,775 shares of the biotechnology company’s stock worth $171,000 after acquiring an additional 10,875 shares during the period. Finally, Millennium Management LLC raised its position in shares of Aduro BioTech by 3.8% in the fourth quarter. Millennium Management LLC now owns 298,441 shares of the biotechnology company’s stock worth $2,238,000 after acquiring an additional 10,991 shares during the period. 44.94% of the stock is currently owned by institutional investors.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.